Navigation Links
DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
Date:4/15/2008

IRVING, Texas, April 15 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that its wholly-owned subsidiary, DelSite Biotechnologies, Inc., entered into a non-exclusive technology evaluation agreement with a global pharmaceutical company for the purpose of evaluating DelSite's GelSite(R) polymer-based delivery technologies.

The goal of the program is to evaluate DelSite's parenteral technologies. DelSite has agreed to provide GelSite polymer and technical information concerning the optimal solubilization and mixing conditions. Terms of the agreement were not disclosed.

Carlton E. Turner, PhD, president and CEO of Carrington Laboratories and DelSite Biotechnologies, commented, "DelSite's technologies are novel and patent-protected, and we are dedicated to developing them for a wide range of applications. This agreement represents another highlight of increased interest in DelSite's technologies within the pharmaceutical industry."

DelSite is currently developing a nasal powder H5N1 influenza vaccine based on the GelVac(TM) nasal powder platform. Advantages of the GelVac vaccine delivery platform are: room temperature stability, needle-free administration, no adjuvant requirement, no preservative requirement, no cold-chain distribution, and induction of both systemic and mucosal immunity. DelSite plans to initiate a Phase I clinical study of the flu vaccine with the GelVac platform this summer.

GelSite polymer is a novel, naturally-occurring ionic carbohydrate polymer that is capable of forming a gel upon contact with body fluids. DelSite has developed three novel delivery platforms for various applications: 1) GelVac nasal powder for nasal delivery of vaccines and therapeutics; 2) GelSure(TM) for injectable delivery of therapeutics; and 3) GPDA(TM) depot adjuvant for vaccine applications. GPDA is a unique depot adjuvant; unlike many current adjuvants, it does not stimulate immune cells but achieves the adjuvant effect through sustained antigen release or depot effect.

DelSite has completed a series of toxicology studies on GelSite polymer and the delivery platforms. A Drug Master File (DMF) for use of GelSite polymer was filed in 2005 with both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA).

About DelSite

Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac formula with the H5N1 avian flu antigen. This work is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institutes of Health) under the Department of Health and Human Services.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, and wound and oral care. Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP drug standards. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington/DelSite may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
2. DelSite Nasal Powder Technology Could Reduce Recently Reported Waste in Federal Vaccine Program
3. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. Monsanto Company Signs Share Subscription Agreement With Devgen
8. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
9. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
10. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
11. Assay Designs(TM) Announces Additions to the Leadership Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):